Research and Markets (http://www.researchandmarkets.com/research/ns5h26/diagnostics) has announced the addition of the "Diagnostics Partnering Terms and Agreements" report to their offering.
The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
Benefits of this Report:
Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of diagnostic deal trends since 2007
- Analysis of the structure of diagnostic agreements with numerous real life case studies
- Comprehensive access to over 2,900 actual diagnostic contracts entered into by the world's biopharma companies
- Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
- Insight into the terms included in a diagnostic agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in diagnostic dealmaking
Chapter 3 - Leading diagnostic deals
Chapter 4 - Bigpharma diagnostic deals
Chapter 5 - Diagnostic dealmaking directory
Chapter 6 - Diagnostic partnering resource center
Appendices
Appendix
About Current Partnering
Table of figures
For more information visit http://www.researchandmarkets.com/research/ns5h26/diagnostics
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.